Related Experiment Videos
A clinical evaluation of genetic stability
E D Gomperts1, S G Courter, M D Lynes
1Baxter Healthcare Corporation, Hyland Division, Glendale, CA.
Developments in Biological Standardization
|January 1, 1994
Summary
Genetic engineering cell line mutations are unlikely to cause adverse effects in biotechnology products. A study on recombinant antihaemophilic factor found no evidence of harm from host cell mutations, deeming it highly improbable.
Area of Science:
- Biotechnology
- Genetics
- Clinical Pharmacology
Background:
- Genetically engineered cell lines are used in biotechnology product manufacturing.
- Theoretical risk exists for mutations in production cell lines leading to aberrant proteins and adverse patient effects.
- Recombinant antihaemophilic factor (rAHF), a complex glycoprotein administered chronically, provides a model to investigate this risk.
Purpose of the Study:
- To investigate the theoretical concern of host cell line mutations causing adverse clinical reactions in patients receiving recombinant antihaemophilic factor.
- To assess if any unanticipated or deleterious effects in patients could be attributed to mutations in the genetically engineered cell line.
Main Methods:
- Retrospective analysis of clinical trial data from patients treated with recombinant antihaemophilic factor.
- Evaluation of various patient data, including clinical efficacy, pharmacokinetic parameters, and inhibitor formation.
- Cross-referencing clinical findings with product characterization information.
Main Results:
- Extensive analysis of patient data provided no evidence to support concerns regarding host cell mutations.
- No unanticipated or adverse events were identified that could be attributed to mutations in the genetically engineered cell line.
- Clinical data and product characterization suggest mutation is a highly improbable event for this recombinant product.
Conclusions:
- The study found no clinical evidence to support the theoretical risk of adverse events due to host cell line mutations in recombinant antihaemophilic factor.
- While absolute exclusion is not possible, the data strongly indicate that mutations in the production cell line are highly improbable and do not pose a significant clinical risk for this product.